and mineral oil comes back… Amarin needs to do something more aggressive about that, or it will continue to appear in the recommendations of all European countries.
LTRO, Thanks for the information. So according to this committee, Vascepa offers no medical benefits. At the same time the EMA has given us a broad label, and the medical societies have declared Vascepa a standard of care. Is this normal procedure for these committees? Sleven,
Thx for the update Basically only for secondary prevention in the R-IT profile ....that the UK NICE will probably match if AMRN gives them a 10-15% discount to meet their QLAY specification . Kiwi